Should you buy Tesco plc, Lloyds Banking Group plc and GlaxoSmithKline plc?

Are FTSE 100 heavyweights Tesco plc (LON:TSCO), Lloyds Banking Group plc (LON:LLOY) and GlaxoSmithKline plc (LON:GSK) worth buying?

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

These three stocks are heavyweights of the FTSE 100 index. Today I’m investigating if any are worth buying in the current economic environment. 

Recovering supermarket

Tesco (LSE: TSCO) released very encouraging first quarter trading results yesterday. Group like for like sales grew by 0.9% and it was the second quarter in a row that like-for-like sales grew. Believe it or not, this was the first time Tesco has seen two consecutive quarters of growth for over five years. The international division grew sales by 3.7%, which is also encouraging and should drive revenue higher this year. The company has also divested a number of assets this year such as the Giraffe chain and Dobbies Garden Centres.

This is all part of the recovery plan and should allow the company to refocus on the core parts of the business. Tesco has also created new fresh food brands that seems to be looking really promising. CEO Dave Lewis commented on the brands stating that: “Our new fresh food brands are performing very well, with over two-thirds of our customers having bought products from the new range.”

Private investor favourite

Shares of Lloyds Banking Group (LSE: LLOY) haven’t been performing very well and are down 34% over the last year. The bank has been performing well and is forecast to pay a 6% dividend yield this year rising to 7% in 2017. The shares look quite cheap too and trade on a forward price-to-earnings ratio (P/E) of just 8.2. Many city analysts believe the shares are undervalued too and a few even have price targets above 95p. That’s a whopping 60% higher than the price you can buy shares for today. For such a big company that pays a chunky dividend it’s an attractive proposition. 

After today’s huge news that the UK will be leaving the EU, Lloyds shares have been hammered. While the company looks like an attractive proposition it may be sensible to sit on the sidelines. There’s so much uncertainty within the UK banking sector that the shares could easily fall further. 

Pharma giant

GlaxoSmithKline (LSE: GSK) is another private investor favourite. It’s another high yielding share as it carries a 5.5% dividend yield covered 1.3 times by cash. Glaxo has had a tough time of late as blockbuster drugs finish patents, which has caused cash flow to decrease. The company has moved to offset this and now has an exciting pipeline of new drugs and treatments set to hit the market in the next few years. This should mean cash flow from sales is boosted higher and the company returns to making consistent profits. 

This new pipeline of drugs opens the door to dividend hikes in the future. The stock already yields over 5% and I think it could be a great addition to any income portfolio. The company currently carries a P/E ratio far lower than main rival AstraZeneca (LSE: AZN) and I believe it’s probably the best pharma play in London. 

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

Jack Dingwall has no position in any shares mentioned. The Motley Fool UK owns shares of and has recommended GlaxoSmithKline. The Motley Fool UK has recommended AstraZeneca. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Affectionate Asian senior mother and daughter using smartphone together at home, smiling joyfully
Investing Articles

How I’d invest my first £20k ISA to target £4,900 a year from dividend shares

Looking for dividend shares in a new Stocks and Shares ISA, and want diversification too? Here's how I'd go about…

Read more »

Passive income text with pin graph chart on business table
Investing Articles

Yields of up to 7%! I’d consider boosting my income with these FTSE dividend stocks

The London market has some decent-looking dividend stocks right now, and I’m tempted by these two for growing income streams.

Read more »

Young mixed-race couple sat on the beach looking out over the sea
Investing Articles

I’d put £20K in an ISA now to target a £1,900 monthly second income in future!

Christopher Ruane shares why he thinks a long-term approach to investing and careful selection of shares could help him build…

Read more »

Mature couple at the beach
Investing Articles

6 stocks that Fools have been buying!

Our Foolish freelancers are putting their money where their mouths are and buying these stocks in recent weeks.

Read more »

Black woman using loudspeaker to be heard
Investing Articles

I was right about the Barclays share price! Here’s what I think happens next

Jon Smith explains why he still feels the Barclays share price is undervalued and flags up why updates on its…

Read more »

Investing Articles

Where I’d start investing £8,000 in April 2024

Writer Ben McPoland highlights two areas of the stock market that he would target if he were to start investing…

Read more »

View of Tower Bridge in Autumn
Investing Articles

Ahead of the ISA deadline, here are 3 FTSE 100 stocks I’d consider

Jon Smith notes down some FTSE 100 stocks in sectors ranging from property to retail that he thinks could offer…

Read more »

Young female business analyst looking at a graph chart while working from home
Investing Articles

Why I think Rolls-Royce shares will pay a dividend in 2024

Stephen Wright thinks Rolls-Royce shares are about to pay a dividend again. But he isn’t convinced this is something investors…

Read more »